Beraprost sodium enhances neovascularization in ischemic myocardium by mobilizing bone marrow cells in rats

Biochemical and Biophysical Research Communications

Volumn 349, Issue 4, 2006, Pages 1242-1249

  Miyahara, Yoshinori ^a   Ohnishi, Shunsuke ^a   Obata, Hiroaki ^a   Ishino, Kozo ^b   Sano, Shunji ^b   Mori, Hidezo ^a   Kangawa, Kenji ^a   Kitamura, Soichiro ^a   Nagaya, Noritoshi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Bone marrow mobilization; Myocardial infarction; Neovascularization; Prostacyclin analogue

Indexed keywords

BERAPROST;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CAPILLARY DENSITY; CELL COUNT; CONTROLLED STUDY; DRUG EFFECT; HEART FUNCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; MALE; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; RAT; STEM CELL MOBILIZATION;

ANIMALS; BONE MARROW CELLS; CARDIOTONIC AGENTS; CELL MOVEMENT; EPOPROSTENOL; MALE; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 33748850756     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.08.178     Document Type: Article

References (42)

1. Saraste A., Pulkki K., Kallajoki M., Henriksen K., Parvinen M., and Voipio-Pulkki L.M. Apoptosis in human acute myocardial infarction. Circulation 95 (1997) 320-323
2. Shintani S., Murohara T., Ikeda H., Ueno T., Honma T., Katoh A., Sasaki K., Shimada T., Oike Y., and Imaizumi T. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103 (2001) 2776-2779
3. Orlic D., Kajstura J., Chimenti S., Jakoniuk I., Anderson S.M., Li B., Pickel J., Mckay R., Nadal-Ginard B., Bodine D.M., Leri A., and Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature 410 (2001) 701-705
4. Oh H., Bradfute S.B., Gallardo T.D., Nakamura T., Gaussin V., Mishina Y., Pocius J., Michael L.H., Behringer R.R., Garry D.J., Entman M.L., and Schneider M.D. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc. Natl. Acad. Sci. USA 100 (2003) 12313-12318
5. Orlic D., Kajstura J., Chimenti S., Limana F., Jakoniuk I., Quaini F., Nadal-Ginard B., Bodine D.M., Leri A., and Anversa P. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc. Natl. Acad. Sci. USA 98 (2001) 10344-10349
6. Asahara T., Takahashi T., Masuda H., Kalka C., Chen D., Iwaguro H., Inai Y., Silver M., and Isner J.M. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18 (1999) 3964-3972
7. Murata T., Murai T., Kanai T., Ogaki Y., Sanai K., Kanda H., Sato S., Kajikawa N., Umetsu T., and Matsuura H. General pharmacology of beraprost sodium. Arzneimittelforschung 39 (1989) 867-876
8. Akiba T., Miyazaki M., and Toda N. Vasodilator actions of TRK-100, a new prostaglandin I2 analogue. Br. J. Pharmacol. 89 (1986) 703-711
9. Nishio S., Matsuura H., Kanai N., Fukatsu Y., Hirano T., Nishikawa N., Kameoka K., and Umetsu T. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. Jpn J. Pharmacol. 47 (1988) 1-10
10. Demolis J.L., Robert A., Mouren M., Funck-Brentano C., and Jaillon P. Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers. J. Cardiovasc. Pharmacol. 22 (1993) 711-716
11. Nony P., Ffrench P., Girard P., Delair S., Azoulay S., Girre J.P., Dechavanne M., and Boissel J.P. Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: a study in healthy male subjects. Can. J. Physiol. Pharmacol. 74 (1996) 887-893
12. Murakami M., Watanabe M., Furukawa H., and Nakahara H. The prostacyclin analogue beraprost sodium prevents occlusion of bypass grafts in patients with lower extremity arterial occlusive disease: a 20-year retrospective study. Ann. Vasc. Surg. 19 (2005) 838-842
13. Cooper L.T. Beraprost for the treatment of intermittent claudication. J. Am. Coll. Cardiol. 41 (2003) 1679-1686
14. Okano Y., Yoshioka T., Shimouchi A., Satoh T., and Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 349 (1997) 1365
15. Nagaya N., Uematsu M., Okano Y., Satoh T., Kyotani S., Sakamaki F., Nakanishi N., Miyatake K., and Kunieda T. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J. Am. Coll. Cardiol. 34 (1999) 1188-1192
16. Lefer A.M., Ogletree M.L., Smith J.B., Silver M.J., Nicolaou K.C., Barnette W.E., and Gasic G.P. Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Science 200 (1978) 52-54
17. Jugdutt B.I., Hutchins G.M., Bulkley B.H., and Becker L.C. Dissimilar effects of prostacyclin, prostaglandin E1, and prostaglandin E2 on myocardial infarct size after coronary occlusion in conscious dogs. Circ. Res. 49 (1981) 685-700
18. Melin J.A., and Becker L.C. Salvage of ischemic myocardium by prostacyclin during experimental myocardial infarction. J. Am. Coll. Cardiol. 2 (1983) 279-286
19. Niwano K., Arai M., Tomaru K., Uchiyama T., Ohyama Y., and Kurabayashi M. Transcriptional stimulation of the eNOS gene by the stable prostacyclin analogue beraprost is mediated through cAMP-responsive element in vascular endothelial cells: close link between PGI2 signal and NO pathways. Circ. Res. 93 (2003) 523-530
20. Aicher A., Heeschen C., Mildner-Rihm C., Urbich C., Ihling C., Technau-Ihling K., Zeiher A.M., and Dimmeler S. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 9 (2003) 1370-1376
21. Nishikimi T., Uchino K., and Frohlich E.D. Effects of α1-adrenergic blockade on intrarenal hemodynamics in heart failure rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 262 (1998) R198-R203
22. Douglas P.S., Reichek N., Plappert T., Muhammad A., and St John Sutton M.G. Comparison of echocardiographic methods for assessment of left ventricular shortening and wall stress. J. Am. Coll. Cardiol. 9 (1987) 945-951
23. Chien Y.W., Barbee R.W., Macphee A.A., Frohlich E.D., and Trippondo N.C. Increased ANF secretion after volume expansion is preserved in rats with heart failure. Am. J. Physiol. 254 (1988) R185-R191
24. Ito T., Suzuki A., Imai E., Okabe M., and Hori M. Bone marrow is a reservoir of repopulating mesangial cells during glomerular remodeling. J. Am. Soc. Nephrol. 12 (2001) 2625-2635
25. Simpson P.J., Todd III R.F., Fantone J.C., Mickelson J.K., Griffin J.D., and Lucchesi B.R. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J. Clin. Invest. 81 (1988) 624-629
26. Nichols W.W., Mehta J., Wargovich T.J., Franzini D., and Lawson D. Reduced myocardial neutrophil accumulation and infarct size following thromboxane synthetase inhibitor or receptor antagonist. Angiology 40 (1989) 209-221
27. Kainoh M., Imai R., Nakadake T., Hattori M., and Nishio S. Prostacyclin and beraprost sodium as suppressors of activated rat polymorphonuclear leukocytes. Biochem. Pharmacol. 39 (1990) 477-483
28. Ueno Y., Miyauchi Y., and Nishio S. Beraprost sodium protects occlusion/reperfusion injury in the dog by inhibition of neutrophil migration. Gen. Pharmacol. 25 (1994) 427-432
29. Kawamoto A., Tkebuchava T., Yamaguchi J., Nishimura H., Yoon Y.S., Milliken C., Uchida S., Masuo O., Iwaguro H., Ma H., Hanley A., Silver M., learney M., Losordo D.W., Isner J.M., and Asahara T. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation 107 (2003) 461-468
30. Kawamoto A., Asahara T., and Losordo D.W. Transplantation of endothelial progenitor cells for therapeutic neovascularization. Cardiovasc. Radiat. Med. 3 (2002) 221-225
31. Weber A., Pedrosa I., Kawamoto A., Himes N., Munasinghe J., Asahara T., Rofsky N.M., and Losordo D.W. Magnetic resonance mapping of transplanted endothelial progenitor cells for therapeutic neovascularization in ischemic heart disease. Eur. J. Cardiothorac. Surg. 26 (2004) 137-143
32. Kajstura J., Rota M., Whang B., Cascapera S., Hosoda T., Bearzi C., Nurzynska D., Kasahara H., Zias E., Bonafe M., Nadal-Ginard B., Torella D., Nascimbene A., Quaini F., Urbanek K., Leri A., and Anversa P. Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ. Res. 96 (2005) 127-137
33. Lanza R., Moore M.A., Wakayama T., Perry A.C., Shieh J.H., Hendrikx J., Leri A., Chimenti S., Monsen A., Nurzynska D., West M.D., Kajstura J., and Anversa P. Regeneration of the infarcted heart with stem cells derived by nuclear transplantation. Circ. Res. 94 (2004) 820-827
34. Uchida Y., Hanai T., Hasegawa K., Kawamura K., and Oshima T. Recanalization of obstructed coronary artery by intracoronary administration of prostacyclin in patients with acute myocardial infarction. Adv. Prostaglandin Thromboxane Leukot. Res. 11 (1983) 377-383
35. Xiao C.Y., Hara A., K Y., Fujino T., Ma H., Okada Y., Takahata O., Yamada T., Murata T., Narumiya S., and Ushikubi F. Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation 104 (2001) 2210-2215
36. Szczeklik A., Szczeklik J., Nizankowski R., and Gluszko P. Prostacyclin for unstable angina. N. Engl. J. Med. 303 (1980) 881
37. Knudtson M.L., Flintoft V.F., Roth D.L., Hansen J.L., and Duff H.J. Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty. J. Am. Coll. Cardiol. 15 (1990) 691-697
38. Kuethe F., Figulla H.R., Herzau M., Voth M., Fritzenwanger M., Opfermann T., Pachmann K., Krack A., Sayer H.G., Gottschild D., and Werner G.S. Treatment with granulocyte colony-stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction. Am. Heart J. 150 (2005) 115
39. Kang H.J., Kim H.S., Zhang S.Y., Park K.W., Cho H.J., Koo B.K., Kim Y.J., Soo Lee D., Sohn D.W., Han K.S., Oh B.H., Lee M.M., and Park Y.B. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 363 (2004) 751-756
40. Califf R.M., Adams K.F., McKenna W.J., Gheorghiade M., Uretsky B.F., McNulty S.E., Darius H., Schulman K., Zannad F., Handberg-Thurmond E., Harrell Jr. F.E., Wheeler W., Soler-Soler J., and Swedberg K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am. Heart J. 134 (1997) 44-54
41. Lievre M., Morand S., Besse B., Fiessinger J.N., and Boissel J.P. Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation 102 (2000) 426-431
42. Mohler III E.R., Hiatt W.R., Olin J.W., Wade M., Jeffs R., and Hirsch A.T. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. J. Am. Coll. Cardiol. 41 (2003) 1679-1686